Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun 1;2(6):e25396.
doi: 10.4161/onci.25396. Epub 2013 Jun 13.

Current trends of anticancer immunochemotherapy

Erika Vacchelli  1 , Nicole Prada, Oliver Kepp, Lorenzo Galluzzi
Affiliations

Current trends of anticancer immunochemotherapy

Erika Vacchelli et al. Oncoimmunology. .
No abstract available

Keywords: MDSCs; antigenicity; cognate immune effectors; immunogenicity; immunosuppressive networks; innate immune effectors.

PubMed Disclaimer

Figures

None
Figure 1. Current approaches of anticancer immunochemotherapy. Among the articles published in OncoImmunology from January 2012 to March 2013, all those describing or commenting the sequential or concomitant administration of distinct immunotherapeutic or chemotherapeutic regimens (both in preclinical and clinical settings) have been identified, and such combinatorial approaches have been classified based on the most prominent immunostimulatory activity of their components. The size of inward bulges and the weight of central connectors reflects the relative proportion of homologous (involving the use of two distinct molecules that exert immunostimulatory effects via the same general mechanism) and heterologous (involving the administration of two agents that promote anticancer immune responses via distinct general mechanisms) combinatorial approaches to immunochemotherapy, respectively.
See this image and copyright information in PMC

References

    1. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov. 2012;11:215–33. doi: 10.1038/nrd3626. - DOI - PubMed
    1. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011;8:151–60. doi: 10.1038/nrclinonc.2010.223. - DOI - PubMed
    1. Prendergast GC. Immunological thought in the mainstream of cancer research: Past divorce, recent remarriage and elective affinities of the future. Oncoimmunology. 2012;1:793–7. doi: 10.4161/onci.20909. - DOI - PMC - PubMed
    1. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy--revisited. Nat Rev Drug Discov. 2011;10:591–600. doi: 10.1038/nrd3500. - DOI - PubMed
    1. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12:237–51. doi: 10.1038/nrc3237. - DOI - PMC - PubMed